Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04564781 · ClinicalTrials.gov registry record
Predicting BCG Response
A clinical trial of Bladder Cancer, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 5
- Study locations
NCT04564781: Recruiting study of Bladder Cancer, sponsored by Cedars-Sinai Medical Center.
NCT04564781 is a study of Bladder Cancer that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 400 participants, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04564781, a study of Bladder Cancer, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 5
- Study locations
Study Summary
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.
Conditions Studied
Study Locations (5)
California
- Cedars-Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- UCSF - San Francisco
Texas
- University of Texas Southwestern - Dallas
Kyoto
- Kyoto University - Kyoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2030-02 |
What NCT04564781 shows while recruiting
NCT04564781 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04564781 lists 5 locations in 3 states (California, Texas, Kyoto).
Frequently Asked Questions
What is clinical trial NCT04564781 about?
NCT04564781 is a clinical study titled "Predicting BCG Response". To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesse...
What is the current status of trial NCT04564781?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2020-09-18. Estimated completion is 2030-02.
What conditions does trial NCT04564781 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT04564781?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04564781 being conducted?
This trial has 5 study locations across California, Texas, Kyoto. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04564781's enrollment target sits among peer trials
400 40th of 175 higher than 135 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI